CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Recruiting now · Phase 1/Phase 2

Conditions studied: Locally Advanced / Metastatic Solid Tumors

In brief

The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with locally advanced or metastatic solid tumors.

Key facts

Study ID
NCT07335497
Run by
Crescent Biopharma, Inc.
People needed
290
Starts
2026-02-17
Expected to finish
2029-02-01
Last updated by the study team
2026-07-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.